FDA Partially Recognizes ISO 10993-1:2025: What Medical Device Manufacturers Must Know About Biological Evaluation, Risk Management & FDA Compliance

Why FDA’s Partial Recognition of ISO 10993-1 Sixth Edition Could Impact Biological Evaluation Strategies, Risk Assessments, and Regulatory Submissions Through 2029

The global medical device industry is entering another important phase of biological safety regulation.

On May 25, 2026, the U.S. Food and Drug Administration (FDA) officially granted partial recognition to the Sixth Edition of ISO 10993-1:2025, the internationally recognized standard governing the biological evaluation of medical devices.

While the recognition supports many aspects of the updated standard, the FDA also identified specific provisions that are not currently recognized, creating important considerations for manufacturers planning future biological evaluation programs and regulatory submissions.

The FDA's announcement has implications for:

• Biological evaluation planning
• Risk management integration
• Device safety assessments
• Regulatory submission strategies
• Genotoxicity evaluations
• Lifecycle risk management
• FDA compliance planning
• Global market access

For medical device manufacturers, understanding these changes is becoming essential for maintaining regulatory readiness and avoiding submission delays.

Executive Overview

ISO 10993-1 serves as the foundation for biological safety assessment of medical devices worldwide.

The newly released Sixth Edition introduces several updates intended to strengthen:

• Biological risk assessment methodologies
• Lifecycle-based evaluation approaches
• Scientific justification requirements
• Risk estimation practices
• Device safety documentation
• Modern toxicological assessment frameworks

However, the FDA's decision to provide only partial recognition highlights the importance of understanding where the standard aligns and where it diverges from current FDA expectations.

The agency specifically identified provisions that may conflict with existing FDA-recognized standards and guidance documents.

As a result, manufacturers must carefully balance:

• ISO 10993-1 implementation
• FDA guidance expectations
• ISO 14971 risk management requirements
• Submission-specific regulatory strategies
• Long-term compliance planning

This development reflects the increasingly complex relationship between international standards and regulatory implementation.

What FDA Recognized and What It Did Not

The FDA has officially recognized much of ISO 10993-1:2025.

However, two notable exceptions were identified.

Exception 1: Clause 6.9 – Biological Risk Estimation

FDA does not recognize Clause 6.9 related to biological risk estimation.

According to the agency, the clause conflicts with specific requirements contained within the currently recognized version of ISO 14971:2019 for medical device risk management.

FDA determined that certain approaches outlined in Clause 6.9 may not align with:

• Established risk management principles
• Existing FDA-recognized standards
• Current regulatory review practices
• Risk-benefit assessment expectations

Manufacturers should therefore continue prioritizing FDA-recognized risk management frameworks when developing biological evaluation strategies.

Exception 2: Clause 6.5.11.3 Language Exclusion

The FDA also excluded the phrase:

"Consumer products or"

from Clause 6.5.11.3.

The agency stated that this wording conflicts with existing FDA final guidance regarding low-risk medical devices that contact intact skin.

This clarification reinforces the FDA's position that biological evaluation requirements for medical devices should remain distinct from consumer product safety frameworks.

Why the FDA Decision Matters

The FDA's recognition announcement extends beyond a simple standards update.

It signals a broader regulatory emphasis on:

• Risk-based biological evaluation
• Scientific justification
• Consistency with FDA guidance
• Lifecycle safety management
• Structured regulatory oversight

Medical device manufacturers increasingly face expectations to demonstrate that biological safety assessments are not merely testing exercises but components of a comprehensive risk management process.

This reflects a growing industry movement toward:

Integrated Biological Risk Management

Key Areas Manufacturers Should Evaluate

Organizations preparing future submissions should assess several operational areas.

Proactive review can help reduce uncertainty during regulatory submissions.

Important FDA Guidance on Implementation

The FDA emphasized that implementation guidance for several new concepts introduced within ISO 10993-1:2025 is still evolving.

Technical experts are currently developing additional reports addressing topics such as:

• Intermittent device contact
• Bioaccumulation considerations
• Reasonably foreseeable misuse
• Lifecycle application of biological evaluation
• Emerging risk assessment methodologies

Until further guidance becomes available, manufacturers should carefully evaluate how these concepts are applied within biological safety programs.

The agency recommends engaging FDA review teams when implementation questions arise.

Understanding the Genotoxicity Evaluation Challenge

One of the most discussed updates in the Sixth Edition involves expanded expectations surrounding genotoxicity evaluation.

The FDA noted that certain new requirements may not fully align with existing FDA guidance for all prolonged-contact devices.

This creates potential uncertainty regarding:

• Test selection strategies
• Biological endpoints
• Toxicological risk assessments
• Submission documentation requirements
• Long-term device safety evaluations

Manufacturers consider implementation of these new approaches are encouraged to consult FDA review offices before initiating biological evaluation programs.

Early engagement can help prevent unnecessary testing and reduce regulatory risk.

Transition Period: What Manufacturers Need to Know

The FDA has established a significant transition period.

Declarations of conformity referencing:

ISO 10993-1:2018

will continue to be accepted until:

July 1, 2029

This transition period provides manufacturers with time to:

• Assess internal procedures
• Update biological evaluation frameworks
• Review testing protocols
• Align risk management systems
• Train regulatory teams
• Modernized submission strategies

Organizations can therefore adopt a structured implementation approach rather than making immediate changes.

Lessons for Global Medical Device Manufacturers

Many manufacturers operate across multiple regulatory jurisdictions.

As international standards evolve, companies increasingly face challenges related to:

• Global standards harmonization
• Regulatory interpretation differences
• Risk management alignment
• Submission consistency
• Lifecycle compliance management

The FDA's partial recognition demonstrates that adoption of international standards does not automatically guarantee identical regulatory acceptance worldwide.

Successful organizations increasingly establish systems capable of supporting:

• Regional regulatory adaptations
• Scientific evidence management
• Global compliance monitoring
• Cross-functional risk assessments
• Continuous regulatory intelligence

The Strategic Shift in Biological Evaluation

Historically, biological evaluation programs often focus primarily on:

• Test execution
• Endpoint completion
• Submission support documentation
• Individual product assessments

Today, regulators increasingly expect:

• Risk-based decision making
• Scientific justification frameworks
• Lifecycle safety oversight
• Integrated risk management
• Continuous compliance visibility

This represents a significant transformation in medical device regulatory expectations.

Why Traditional Compliance Models Are No Longer Enough

Many manufacturers still rely on:

• Fragmented biological evaluation files
• Manual risk assessment processes
• Isolated testing programs
• Reactive compliance approaches
• Disconnected documentation systems

These approaches can create challenges when responding to evolving regulatory expectations.

Key Operational Challenges

Organizations increasingly require structured compliance systems that connect biological evaluation, risk management, and regulatory strategy.

The Rise of Lifecycle-Based Biological Safety Management

The future of biological evaluation is becoming increasingly:

Risk-Driven & Lifecycle Focused

Leading manufacturers are investing in:

• Digital compliance platforms
• Biological evaluation management systems
• Regulatory intelligence tools
• Integrated risk management frameworks
• Data-driven safety assessments
• Lifecycle monitoring programs

These systems improve:

• Submission readiness
• Audit preparedness
• Regulatory agility
• Documentation consistency
• Safety oversight
• Global compliance scalability

Organizations that modernize early are better positioned to adapt to evolving FDA expectations.

Future Trends Defining Biological Evaluation Compliance

The direction is increasingly clear:

The future of biological evaluation is becoming more risk-driven, science-based, and lifecycle oriented.

Why Regulatory Readiness Is Becoming a Competitive Advantage

The next generation of medical device leaders will compete not only innovation.

They will also compete on:

• Regulatory agility
• Scientific rigor
• Compliance infrastructure
• Risk management maturity
• Lifecycle oversight capabilities
• Global regulatory intelligence

Organizations with mature biological evaluation systems will:

• Adapt faster to regulatory changes
• Reduce submission uncertainty
• Improve FDA interactions
• Strengthen compliance readiness
• Accelerate global market access

How Maven Regulatory Solutions Supports Medical Device Compliance

Our Expertise Includes

• ISO 10993 biological evaluation strategy
• FDA regulatory compliance support
• Biological risk assessment review
• ISO 14971 integration support
• Genotoxicity evaluation planning
• Regulatory intelligence monitoring
• Global medical device compliance strategy
• Lifecycle compliance management
• Submission readiness assessments

Why Companies Choose Maven

• Global medical device regulatory expertise
• Science-driven compliance solutions
• Risk-based regulatory strategies
• End-to-end lifecycle support
• Integrated compliance management frameworks
• Future-focused regulatory planning

Conclusion

The FDA's partial recognition of ISO 10993-1:2025 represents more than a standards update.

It highlights the growing importance of aligning biological evaluation programs with broader risk management and regulatory expectations.

Manufacturers must carefully evaluate:

• Biological risk assessment methodologies
• Risk management integration
• Genotoxicity evaluation approaches
• Lifecycle safety strategies
• Submission planning frameworks

While the transition period extends through July 2029, organizations that begin preparation early will be better positioned to navigate evolving FDA expectations and future regulatory developments.

The most successful manufacturers will not simply update their biological evaluation files.

They will build integrated, science-driven compliance ecosystems capable of supporting long-term regulatory success.

Preparing for ISO 10993-1:2025 Implementation?

At Maven Regulatory Solutions, we help medical device manufacturers evaluate biological safety strategies, align risk management frameworks, and prepare robust compliance programs for evolving FDA expectations.

Our Services Include:

• ISO 10993 biological evaluation support
• FDA compliance assessments
• Risk management integration reviews
• Genotoxicity strategy evaluation
• Regulatory intelligence monitoring
• Submission readiness assessments
• Global medical device compliance support
• Lifecycle compliance management

Connect with our regulatory experts today to strengthen your biological evaluation strategy and prepare for the future of medical device compliance.

FAQ

1. What is ISO 10993-1:2025?

ISO 10993-1:2025 is the Sixth Edition of the international standard governing biological evaluation and risk assessment of medical devices.

2. Did the FDA fully recognize ISO 10993-1:2025?

No. The FDA granted partial recognition and excluded certain provisions that conflict with existing FDA-recognized standards and guidance.

3. Why was Clause 6.9 not recognized?

FDA determined that Clause 6.9 on biological risk estimation conflicts with aspects of the currently recognized ISO 14971:2019 risk management standard.

4. What is the FDA's position on the new genotoxicity requirements?

FDA noted that some new genotoxicity evaluation expectations may not fully align with current agency guidance and recommend consultation with review offices when needed.

5. How long can manufacturers continue using ISO 10993-1:2018?

FDA will accept declarations of conformity to ISO 10993-1:2018 until July 1, 2029.